Flag of the European Union EU Clinical Trials Register Help

Clinical trials for No Smoking Day

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

  • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).


    The EU Clinical Trials Register currently displays   44347   clinical trials with a EudraCT protocol, of which   7375   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    553 result(s) found for: No Smoking Day. Displaying page 6 of 28.
    EudraCT Number: 2012-004966-16 Sponsor Protocol Number: CQVA149A2318 Start Date*: 2013-02-27
    Sponsor Name:Novartis Pharma AG
    Full Title: A 52-week treatment, multi-center, randomized, double-blind, double-dummy, parallel-group, active controlled study to compare the effect of QVA149 (indacaterol maleate / glycopyrronium bromide) wit...
    Medical condition: subjects with moderate to very severe COPD
    Disease: Version SOC Term Classification Code Term Level
    14.1 100000004855 10010953 COPD exacerbation LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: SK (Completed) HU (Completed) SE (Completed) ES (Completed) AT (Completed) LT (Completed) NL (Completed) CZ (Completed) FI (Completed) DE (Completed) BE (Completed) IS (Completed) IT (Completed) PT (Completed) NO (Completed) PL (Completed) EE (Completed) DK (Completed) BG (Completed) LV (Completed) GR (Completed) GB (Completed) LU (Completed)
    Trial results: View results
    EudraCT Number: 2010-023444-32 Sponsor Protocol Number: DB2114418 Start Date*: 2011-04-27
    Sponsor Name:GlaxoSmithKline
    Full Title: An exercise endurance study to evaluate the effects of treatment of COPD patients with a dual bronchodilator: GSK573719/GW642444.
    Medical condition: Chronic Obstructive Pulmonary Disease (COPD)
    Disease: Version SOC Term Classification Code Term Level
    12.1 10010952 COPD LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: CZ (Completed) GB (Completed) DK (Completed)
    Trial results: View results
    EudraCT Number: 2012-002156-16 Sponsor Protocol Number: DB2114951 Start Date*: 2014-08-13
    Sponsor Name:GlaxoSmithKline Research & Development Limited
    Full Title: A randomized, multi-center, double-blind, doubledummy, parallel group study to evaluate the efficacy and safety of umeclidinium/vilanterol compared with fluticasone propionate/salmeterol over 12...
    Medical condition: Chronic Obstructive Pulmonary Disease (COPD)
    Disease: Version SOC Term Classification Code Term Level
    17.0 100000004855 10010952 COPD LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: RO (Completed)
    Trial results: View results
    EudraCT Number: 2017-000495-28 Sponsor Protocol Number: 132 Start Date*: 2017-05-18
    Sponsor Name:Respiratory Research Unit, Bispebjerg University Hospital
    Full Title: SIGNATURE - the 6-gene signature as a predictor of response to treatment in severe asthma and ACOS
    Medical condition: Severe asthma and astma-COPD overlap syndrome
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004855 10077006 Asthma-COPD overlap syndrome LLT
    20.0 100000004855 10003561 Asthma, unspecified LLT
    20.0 100000004855 10068462 Eosinophilic asthma LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DK (Completed)
    Trial results: View results
    EudraCT Number: 2009-015901-38 Sponsor Protocol Number: M/40464/26 Start Date*: 2010-02-02
    Sponsor Name:ALMIRALL, S.A.
    Full Title: Efficacy, safety and tolerability of two Fixed-Dose Combinations of Aclidinium bromide with two doses of Formoterol fumarate compared with Aclidinium bromide, Formoterol fumarate and placebo all ad...
    Medical condition: Moderate to severe chronic obstructive pulmonary disease (COPD)
    Disease: Version SOC Term Classification Code Term Level
    12.0 10009033 Chronic obstructive pulmonary disease LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed) HU (Completed) CZ (Completed) RO (Completed)
    Trial results: View results
    EudraCT Number: 2012-000525-45 Sponsor Protocol Number: DB2114930 Start Date*: 2013-01-10
    Sponsor Name:GlaxoSmithKline Research & Development Limited
    Full Title: DB2114930: A randomized, multi-center, double-blind, doubledummy, parallel group study to evaluate the efficacy and safety of umeclidinium/vilanterol compared with fluticasone propionate/salmetero...
    Medical condition: Chronic Obstructive Pulmonary Disease (COPD)
    Disease: Version SOC Term Classification Code Term Level
    14.1 100000004855 10010952 COPD LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GR (Completed)
    Trial results: View results
    EudraCT Number: 2016-003675-21 Sponsor Protocol Number: 205724 Start Date*: 2017-06-01
    Sponsor Name:GlaxoSmithKline, S.A.
    Full Title: Randomised, Double-Blind (Sponsor Open), Placebo-Controlled, Multicentre, Dose Ranging Study to Evaluate the Efficacy and Safety of Danirixin Tablets Administered Twice Daily Compared With Placebo ...
    Medical condition: Chronic obstructive pulmonary disease
    Disease: Version SOC Term Classification Code Term Level
    19.1 100000004855 10010952 COPD LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: ES (Completed) DE (Completed) NL (Completed) PL (Completed) RO (Completed)
    Trial results: View results
    EudraCT Number: 2007-000010-36 Sponsor Protocol Number: M/34273/25 Start Date*: 2007-10-18
    Sponsor Name:Laboratorios Almirall, S.A.
    Full Title: A multiple dose, double-blind, double-dummy, 3 period cross-over, placebo controlled clinical trial to assess the efficacy and safety of once daily inhaled aclidinium bromide 200 µg given either in...
    Medical condition: Stable moderate to severe Chronic Obstructive Pulmonary Disease (COPD)
    Disease: Version SOC Term Classification Code Term Level
    9.1 10009033 Chronic obstructive pulmonary disease LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed) GB (Completed)
    Trial results: View results
    EudraCT Number: 2014-000529-19 Sponsor Protocol Number: 201211 Start Date*: 2014-05-22
    Sponsor Name:GlaxoSmithKline R&D
    Full Title: A 12 week, Multicenter, Randomized, Double-Blind, Parallel-Group, Placebo-Controlled Study to Evaluate the Efficacy of Umeclidinium/Vilanterol 62.5/25mcg in Subjects with COPD
    Medical condition: Subjects with COPD
    Disease: Version SOC Term Classification Code Term Level
    16.1 100000004855 10010952 COPD LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: HU (Completed) DE (Completed) RO (Completed) BG (Completed)
    Trial results: View results
    EudraCT Number: 2020-000619-58 Sponsor Protocol Number: 19CH214 Start Date*: 2021-02-01
    Sponsor Name:CHU SAINT-ETIENNE
    Full Title: A pilot study assessing the feasibility of a randomized controlled trial evaluating aspirin in postpartum women at risk of developing venous thromboembolism Pilot PARTUM Trial: Postpartum Aspirin...
    Medical condition: Post-Partum Venous thromboembolism prophylaxis
    Disease: Version SOC Term Classification Code Term Level
    21.1 100000004865 10049909 Venous thromboembolism prophylaxis LLT
    Population Age: Adults Gender: Female
    Trial protocol: FR (Prematurely Ended) NL (Completed)
    Trial results: (No results available)
    EudraCT Number: 2008-003780-38 Sponsor Protocol Number: P05575 Start Date*: 2009-10-27
    Sponsor Name:Schering-Plough Research Institute
    Full Title: A 2-Year, Dose Range-Finding, Adaptive-Design Study of the Effects of SCH 527123 in Subjects With Moderate to Severe COPD
    Medical condition: COPD
    Disease: Version SOC Term Classification Code Term Level
    9.1 10009033 Chronic obstructive pulmonary disease LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed) FR (Completed) CZ (Prematurely Ended) SK (Completed) GR (Prematurely Ended) IT (Prematurely Ended) GB (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2010-023349-32 Sponsor Protocol Number: DB2113373 Start Date*: 2011-05-26
    Sponsor Name:GlaxoSmithKline, S.A.
    Full Title: A 24-Week, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of GSK573719/GW642444 Inhalation Powder and the Individual Components Delivered Once-Daily via a N...
    Medical condition: Chronic Obstructive Pulmonary Disease (COPD)
    Disease: Version SOC Term Classification Code Term Level
    13.1 10038738 - Respiratory, thoracic and mediastinal disorders 10009033 Chronic obstructive pulmonary disease PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: ES (Completed) CZ (Completed) GR (Completed) PL (Completed) BG (Completed)
    Trial results: View results
    EudraCT Number: 2011-000834-12 Sponsor Protocol Number: M/34273/39 Start Date*: 2011-10-04
    Sponsor Name:Almirall S.A.
    Full Title: A MULTIPLE DOSE, DOUBLE-BLIND, DOUBLE-DUMMY, PLACEBO CONTROLLED, PARALLEL CLINICAL TRIAL TO ASSESS THE EFFICACY AND SAFETY OF TWICE DAILY INHALED ACLIDINIUM BROMIDE 400 μg COMPARED TO PLACEBO AND T...
    Medical condition: Chronic obstructive pulmonary disease (COPD)
    Disease: Version SOC Term Classification Code Term Level
    14.1 10038738 - Respiratory, thoracic and mediastinal disorders 10010952 COPD LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed) HU (Completed) CZ (Completed) PL (Completed)
    Trial results: View results
    EudraCT Number: 2007-004466-41 Sponsor Protocol Number: A6631011 Start Date*: 2008-02-26
    Sponsor Name:Pfizer Ltd, Ramsgate Road, Sandwich, Kent
    Full Title: A PHASE II, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARALLEL GROUP STUDY TO EVALUATE THE EFFICACY AND SAFETY OF ONCE-DAILY ORALLY ADMINISTERED PH-797804 (0.5, 3, 6 AND 10 MG) IN ADULTS WITH M...
    Medical condition: Chronic Obstructive Pulmonary Disease
    Disease: Version SOC Term Classification Code Term Level
    9.1 10010952 COPD LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Completed) CZ (Completed) FR (Completed) GR (Completed) NL (Completed) HU (Completed)
    Trial results: View results
    EudraCT Number: 2013-003073-10 Sponsor Protocol Number: CTT116853 Start Date*: 2014-09-16
    Sponsor Name:GlaxoSmithKline Research and Development
    Full Title: A Phase III, 24 week, randomized, double blind, double dummy, parallel group study (with an extension to 52 weeks in a subset of subjects) comparing the efficacy, safety and tolerability of the fix...
    Medical condition: Chronic Obstructive Pulmonary Disease
    Disease: Version SOC Term Classification Code Term Level
    17.0 10038738 - Respiratory, thoracic and mediastinal disorders 10009033 Chronic obstructive pulmonary disease PT
    Population Age: Adults Gender: Male, Female
    Trial protocol: IT (Completed) SK (Completed) GR (Completed) DE (Completed) CZ (Completed) PL (Completed) BG (Completed) EE (Completed) HU (Completed)
    Trial results: View results
    EudraCT Number: 2011-003588-31 Sponsor Protocol Number: CCD-1106-PR-0066 Start Date*: 2012-02-03
    Sponsor Name:Chiesi Farmaceutici S.p.A.
    Full Title: A multicentre, randomised, double-blind, active-controlled, 4-way cross-over study to evaluate the efficacy and safety of a free combination of 3 doses of Glycopyrrolate with fixed combination Becl...
    Medical condition: Chronic Obstructive Pulmonary Disease
    Disease: Version SOC Term Classification Code Term Level
    14.1 10038738 - Respiratory, thoracic and mediastinal disorders 10009033 Chronic obstructive pulmonary disease PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Completed) DE (Completed) HU (Completed) IT (Completed) PL (Completed)
    Trial results: View results
    EudraCT Number: 2009-014551-80 Sponsor Protocol Number: 1268.16 Start Date*: 2010-01-21
    Sponsor Name:BOEHRINGER ING.
    Full Title: Randomised, double-blind, double-dummy, placebo-controlled, parallel group study to assess the efficacy and safety of 6 weeks of oral BI 671800 ED 400 mg b.i.d., Montelukast 10 mg q.d., or placeb...
    Medical condition: patients with symptomatic asthma on inhaled corticosteroids
    Disease: Version SOC Term Classification Code Term Level
    12.1 10049106 Asthma chronic LLT
    Population Age: Adults Gender: Male, Female
    Trial protocol: IT (Completed) SE (Completed) DE (Completed) GB (Completed) AT (Completed)
    Trial results: View results
    EudraCT Number: 2011-002665-38 Sponsor Protocol Number: M/34273/40 Start Date*: 2011-10-05
    Sponsor Name:Almirall S.A.
    Full Title: A MULTIPLE DOSE, RANDOMISED, DOUBLE-BLIND, PLACEBO CONTROLLED, 2 PERIOD CROSSOVER CLINICAL TRIAL TO ASSESS THE EFFECT OF ACLIDINIUM BROMIDE 400 μg BID ON EXERCISE ENDURANCE IN PATIENTS WITH STABLE ...
    Medical condition: Chronic obstructive pulmonary disease (COPD)
    Disease: Version SOC Term Classification Code Term Level
    14.0 10038738 - Respiratory, thoracic and mediastinal disorders 10010952 COPD LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed) GB (Completed) ES (Completed)
    Trial results: View results
    EudraCT Number: 2005-005804-17 Sponsor Protocol Number: M/34273/24 Start Date*: 2007-02-08
    Sponsor Name:Laboratorios Almirall, S.A.
    Full Title: A Single Dose, Double-Blind, Double-Dummy, 3 Period Cross-Over, Placebo Controlled Clinical Trial To Assess the Rate of Onset of Action of Inhaled LAS 34273 200µg Compared To Placebo and Tiotropium...
    Medical condition: Phase III placebo controlled crossover trial to better characterise the acute effect of LAS 34273 on bronchodilation action in severe COPD patients.
    Disease: Version SOC Term Classification Code Term Level
    8.1 10009033 Chronic obstructive pulmonary disease LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: NL (Completed) DE (Completed) GB (Completed)
    Trial results: View results
    EudraCT Number: 2014-002667-15 Sponsor Protocol Number: 05201401 Start Date*: 2014-09-23
    Sponsor Name:Medizinische Universität Innsbruck, Innere Medizin VI
    Full Title: Effect of Dual Bronchodilatation on Broncholysis Testing in COPD Patients
    Medical condition: COPD (chronic obstructive pulmonary disease)
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: AT (Completed)
    Trial results: View results
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Fri Jul 04 17:08:37 CEST 2025 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA